Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Gossamer Bio Inc (GOSS)

Gossamer Bio Inc (GOSS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 184,977
  • Shares Outstanding, K 225,582
  • Annual Sales, $ 0 K
  • Annual Income, $ -179,820 K
  • 60-Month Beta 1.71
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.08
Trade GOSS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.39
  • Most Recent Earnings $-0.21 on 03/05/24
  • Latest Earnings Date 05/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 324.19% ( -22.80%)
  • Historical Volatility 64.47%
  • IV Percentile 98%
  • IV Rank 82.81%
  • IV High 388.12% on 06/09/23
  • IV Low 16.23% on 05/16/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 25
  • Volume Avg (30-Day) 127
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 21,658
  • Open Int (30-Day) 20,623

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.19
  • Number of Estimates 4
  • High Estimate -0.15
  • Low Estimate -0.23
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +63.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7901 +2.01%
on 04/18/24
1.4400 -44.03%
on 03/19/24
-0.5740 (-41.59%)
since 03/18/24
3-Month
0.7590 +6.19%
on 01/25/24
1.6000 -49.63%
on 03/07/24
-0.0637 (-7.32%)
since 01/18/24
52-Week
0.4525 +78.12%
on 10/24/23
1.8800 -57.13%
on 07/20/23
-0.1737 (-17.73%)
since 04/18/23

Most Recent Stories

More News
Gossamer Bio: Q4 Earnings Snapshot

Gossamer Bio: Q4 Earnings Snapshot

GOSS : 0.8060 (-1.71%)
Gossamer Bio: Q3 Earnings Snapshot

Gossamer Bio: Q3 Earnings Snapshot

GOSS : 0.8060 (-1.71%)
Gossamer Bio: Q2 Earnings Snapshot

Gossamer Bio: Q2 Earnings Snapshot

GOSS : 0.8060 (-1.71%)
Gossamer Bio: Q1 Earnings Snapshot

Gossamer Bio: Q1 Earnings Snapshot

GOSS : 0.8060 (-1.71%)
Gossamer Bio: Q4 Earnings Snapshot

Gossamer Bio: Q4 Earnings Snapshot

GOSS : 0.8060 (-1.71%)
Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation...

GOSS : 0.8060 (-1.71%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors...

GOSS : 0.8060 (-1.71%)
Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?

Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GOSS : 0.8060 (-1.71%)
Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Gossamer Bio (GOSS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates...

GOSS : 0.8060 (-1.71%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors...

GOSS : 0.8060 (-1.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Gossamer Bio Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, inflammation and oncology. The company's product pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology...

See More

Key Turning Points

3rd Resistance Point 0.9155
2nd Resistance Point 0.8873
1st Resistance Point 0.8466
Last Price 0.8060
1st Support Level 0.7777
2nd Support Level 0.7495
3rd Support Level 0.7088

See More

52-Week High 1.8800
Fibonacci 61.8% 1.3347
Fibonacci 50% 1.1662
Fibonacci 38.2% 0.9978
Last Price 0.8060
52-Week Low 0.4525

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar